UCB 2016 Half-Year Management Report

UCB's half-year management report for 2016 presenting net sales of €1,877 million with 10% growth and updates on its pharmaceutical pipeline including development programs in osteoporosis and other therapeutic areas. The report outlines the company's progress on its growth strategy across biologic and molecular therapies.